Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1821 results
July 2017
-
Media ReleaseLes résultats du T2 confirment les prévisions de l'exercice 2017. Les très bons résultats du pipeline étayent le potentiel de plusieurs produits hautement novateursChiffre d'affaires net comparable à celui du T2 de l'exercice précédent (0% tcc[1], -2% en USD), car les moteurs de croissance ont compensé l'impact des génériques de Gleevec/Glivec: Cosentyx (…
-
Media ReleaseQ2 results confirm full year guidance. Strong pipeline results underpin potential of several highly innovative productsNet sales in line with prior year (0% cc[1], -2% USD), as growth drivers offset Gleevec/Glivec Gx impact: Cosentyx (USD 490 million, +90% cc) continues strong growth in all three indications…
-
Media ReleaseNovartis confirms 5 year data for first and only fully-human IL-17A inhibitor Cosentyx® reinforcing sustained efficacy and safety profile in psoriasis5 year data from long-term Phase III extension study demonstrate sustained efficacy and safety of Cosentyx in patients with moderate-to-severe plaque psoriasis[1] Data planned to be…
-
Media ReleaseNovartis CAR-T cell therapy CTL019 unanimously (10-0) recommended for approval by FDA advisory committee to treat pediatric, young adult r/r B-cell ALLRecommendation based on review of CTL019 r/r B-cell ALL development program, including the pivotal Phase II global ELIANA trial A Biologics License Application (BLA) for this indication is…
-
A researcher seeks the roots of plants’ healing power
Deep in a forest in the West African country of Ghana, two men are searching for plants that they hope could ultimately provide a cure for some of the world’s deadliest diseases.
-
In The NewsIncreasing access to NCD treatments in UgandaNovartis reaches agreement with Uganda to supply medicines that address the rapid rise of chronic diseases in the country. Uganda becomes the fifth country to launch Novartis Access.
-
Media ReleaseNovartis receives approval in the EU for Cosentyx label update, includes long term superiority data versus Stelara in psoriasisLabel update includes 52 week data from CLEAR study demonstrating long-term superiority of Cosentyx® versus Stelara® in psoriasis [1],[2] Update also includes use of Cosentyx in moderate-to…
-
Featured NewsAlcon survey reveals that people are happier and more satisfied with their lives after cataract surgery
June 2017
-
Media ReleaseNovartis receives EU approval for first-line use of Zykadia® in ALK-positive advanced non-small cell lung cancer (NSCLC)In ALK-positive advanced NSCLC patients, Zykadia demonstrated superior median progression-free survival (PFS) compared to SOC chemotherapy with maintenance[1] Zykadia benefit was also seen…
-
Media ReleaseSandoz receives approval in Europe for Erelzi® (biosimilar etanercept) to treat multiple inflammatory diseasesEuropean Commission approves Sandoz Erelzi® to treat immunological diseases such as rheumatoid arthritis, psoriasis, and psoriatic arthritis Approval of Erelzi provides more treatment options for…
-
A patient’s perspective on biomarker testing
A lung cancer patient describes her path to diagnosis and what came next.
-
Media ReleaseNEJM publishes full analysis of Rydapt® (midostaurin) Phase III RATIFY trial in newly diagnosed FLT3-mutated acute myeloid leukemia (AML)Significant overall survival benefit observed for FLT3+ AML patients consistent across FLT3 mutation subgroups, including ITD and TKD Detailed data show Rydapt plus standard chemotherapy improved…
Pagination
- ‹ Previous page
- 1
- …
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- …
- 152
- › Next page